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Abstract
Background
Alzheimer’s Disease (AD) can cause degeneration in the retina and optic nerve either
directly, as a result of amyloid beta deposits, or secondarily, as a result of the degradation of
the visual cortex. These effects raise the possibility that tracking ophthalmologic changes in
the retina can be used to assess neurodegeneration in AD. This study aimed to detect reti-
nal changes and associated functional changes in three groups of patients consisting of AD
patients with mild disease, AD patients with moderate disease and healthy controls by using
non-invasive psychophysical ophthalmological tests and optical coherence tomography
(OCT).
Methods
We included 39 patients with mild AD, 21 patients with moderate AD and 40 age-matched
healthy controls. Both patients and controls were ophthalmologically healthy. Visual acuity,
contrast sensitivity, colour perception, visual integration, and choroidal thicknesses were
measured. In addition, OCT and OCT angiography (OCTA) were applied.
Findings
Visual acuity, contrast sensitivity, colour perception, and visual integration were significantly
lower in AD patients than in healthy controls. Compared to healthy controls, macular thin-
ning in the central region was significant in the mild AD patients, while macular thickening in
the central region was found in the moderate AD group. The analysis of macular layers
revealed significant thinning of the retinal nerve fibre layer, the ganglion cell layer and the







Citation: Salobrar-Garcı´a E, de Hoz R, Ramı´rez AI,
Lo´pez-Cuenca I, Rojas P, Vazirani R, et al. (2019)
Changes in visual function and retinal structure in
the progression of Alzheimer’s disease. PLoS ONE
14(8): e0220535. https://doi.org/10.1371/journal.
pone.0220535
Editor: Steven Barnes, Doheny Eye Institute/UCLA,
UNITED STATES
Received: March 26, 2019
Accepted: July 17, 2019
Published: August 15, 2019
Copyright: © 2019 Salobrar-Garcı´a et al. This is an
open access article distributed under the terms of
the Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the manuscript and its Supporting
Information files.
Funding: This work are supported by the
Ophthalmological Network OFTARED of the
Institute of Health of Carlos III of the Spanish
Ministry of Economy (grant RD16/0008/0005 to
ES-G, RdH, AIR, JJS, and JMR; and grant RD16/
0008/0022 to MDP-D; Enfermedades oculares:
"Prevencio´n, deteccio´n precoz, tratamiento y
rehabilitacio´n de las patologı´as oculares"). ES-G
outer plexiform layer in AD patients relative to controls. Conversely, significant thickening
was observed in the outer nuclear layer of the patients. However, mild AD was associated
with significant thinning of the subfovea and the nasal and inferior sectors of the choroid.
Significant superonasal and inferotemporal peripapillary thinning was observed in patients
with moderate disease.
Conclusions
The first changes in the mild AD patients appear in the psychophysical tests and in the cen-
tral macula with a decrease in the central retinal thickness. When there was a disease pro-
gression to moderate AD, psychophysical tests remained stable with respect to the
decrease in mild AD, but significant thinning in the peripapillary retina and thickening in the
central retina appeared. The presence of AD is best indicated based on contrast sensitivity.
Introduction
Alzheimer’s disease (AD), a neurodegenerative disorder related to age, is produced by a
neuronal loss and synapses in the cerebral cortex [1]. The extracellular plaque forming deposits
of the protein amyloid-β (Aβ) and the intraneuronal accumulations of the hyperphosphory-
lated microtubule-associated protein tau, which forms the neurofibrillary tangles [2], charac-
terize this disease. In addition to age, other risk factors include genetic alterations, such as
mutations in the gene that encodes the precursor of Aβ protein or the presence of APOE ε4
allele [3,4].
AD is the most common type of dementia in the world [5] contributing to 60–70% of all
cases [6]. In the last few decades, there have been important advances in the diagnosis of AD.
The retina is a projection of the central nervous system (CNS), and its peripheral location can
provide an accessible and non-invasive path leading to the examination of brain pathology
[7,8]. Due to these characteristics, the visual and structural tests used in the diagnosis of oph-
thalmological diseases can be used as valuable tools to confirm the diagnosis of neurodegener-
ative diseases.
Due to the irreversible course and the absence of an effective treatment for AD, it is essen-
tial to perform the diagnosis at an early stage. In addition, patients should be properly classi-
fied according to each stage of their disease. Within the test that value these capabilities,
Folstein, in 1975, developed the Mini Mental State Examination (MMSE) Folstein et al 1975
[9] which meant an enormous contribution to the assessment of AD patients compared to
other short test that explored only short-term memory. The MMSE explores five areas: orien-
tation, registration, attention and calculation, and memory and language. Based on these two
premises, namely early diagnosis and MMSE, we have classified our AD patients into two
groups: mild AD (25.18±3.80) and moderate AD (19.89±2.76). The study aimed to:
• analyse the changes that take place in the mild AD group, and the moderate AD group by
using psychophysical and structural tests,
• compare these two groups with a population of healthy age-matched controls,
• assess whether there was a progression in these AD groups.
To the best of our knowledge, few studies analyse a plethora of tests and their prognostic
value in the two early stages of AD.
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Methods
Subjects
To select patients, we reviewed the Database of the Memory Unit of the Hospital Clinico San
Carlos in Madrid (Spain), consisting of a total of 3411 patients (Fig 1). We first excluded the
patients with an MMSE lower than 17 followed by those with a mood or psychiatric disorder.
Fig 1. Flow diagram patient’s inclusion.
https://doi.org/10.1371/journal.pone.0220535.g001
Visual function and retina in Alzheimer’s progression
PLOS ONE | https://doi.org/10.1371/journal.pone.0220535 August 15, 2019 3 / 23
Next, we considered patients with mild AD and moderate AD. These patients, according to
the National Institute of Neurological and Communicative Disorders and Stroke-AD and
Related Disorders Association and the Diagnostic (NINCDS-ADRDA) and Statistical Manual
of Mental Disorders IV (DSM IV), had mild and moderate cognitive impairments according
to the Clinical Dementia Rating scale (CDR). Then, ophthalmic medical records of these
patients, excluding those who were previously diagnosed with an ophthalmological pathology
(glaucoma or suspected glaucoma, media opacity, and retinal diseases) were reviewed. After
this analysis, 122 patients with AD satisfied all the requirements (having an MMSE of over 17
and being free of ocular disease and systemic disorders affecting vision in their medical record)
needed to participate in the study. Aged-matched control subjects were healthy controls from
the Geriatric Unit of the Hospital Clı´nico San Carlos (Madrid) (n = 37) or the relatives of AD
patients (husband or wife) with no history of memory decline and MMSE>25 (n = 3). Of the
122 AD patients and 60 age-matched control subjects selected, 62 AD patients and 40 age-
matched control subjects were subsequently excluded due to posterior pole pathology, which
included macular degeneration, drusen, suspicion of glaucoma, glaucoma, epiretinal mem-
brane, or cataracts, all of which prevented ocular examination. Because of this selection, 39
patients with mild AD, 21 patients with moderate AD and 40 age-matched control subjects
were considered for the study. All patients had adequate reasoning faculties and be in posses-
sion of all relevant facts to give the written informed consent. Written informed consent was
obtained from these three groups. The research followed the tenets of the Declaration of Hel-
sinki, and the protocol was approved by the local ethics committee (CEIC Hospital Clinico
San Carlos 11/372-E). In S1 File there are all the study’s underlying data set.
Methods
The clinical evaluation of our AD included a review of the medical records, a caregiver inter-
view, physical and neurological examinations, a psychometric test, neuroimaging techniques,
and routine laboratory testing for dementia. In the ophthalmological part of the study, only
one eye of each patient was analysed. All participants met the following inclusion criteria:
being free of ocular disease, having AREDS Clinical Lens Standards affecting vision, having a
best-corrected visual acuity (VA) of 0.5 dec, having less than ±5 spherocylindrical refractive
error, and having intraocular pressure of less than 20 mmHg. For screening, all AD patients
and control subjects underwent a complete ophthalmologic examination, including VA,
refraction, anterior segment biomicroscopy, applanation tonometry (Perkins MKII tonome-
ter), CS test CSV-1000E, Roth 28-hue colour test, a perception digital test (PDT) [10], a dilated
fundus examination and an OCT.
Visual acuity
The monocular best-corrected VA was determined using a standard clinical Snellen eye chart
(decimal scale). The patients started to read each row from the top of the Snellen eye chart and
proceeded towards the bottom. This process ended when the hit rate was less than five of eight
(an approximation of 56.25%, the steepest point of the psychometric acuity function).
Contrast sensitivity function
The CS test was performed with the CSV-1000E system (VectorVision, Greenville, OH, USA)
and in the presence of the best-corrected VA for far vision. The patient was encouraged to
guess whether a grating was at least partially visible as the threshold was approached. The con-
trast level of the last correct response was recorded as the threshold.
Visual function and retina in Alzheimer’s progression
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Colour perception
To administer a colour-vision test that did not require a naming response, we used Roth
28-Hue Color Test (Luneau, Paris), a quick and easy colour arrangement test first described by
Roth [11]. Colour perception was assessed in the presence of best-corrected VA for near
vision. Test instructions were repeated by the examiner during the test when necessary. The
time to perform the test was not restricted, and the subject was allowed to make corrections.
Errors classified the observer as protanomalous, deuteranomalous, or tritanomalous (red-,
green-, or blue-deficient, resp.). The manufacturer’s manual blue axis errors were considered
when caps 43 to 64 were malpositioned and deutan axis errors were between caps 42 to 85.
Thus, the tritan and deutan errors were quantified.
Perception Digital Test (PDT)
The PDT [10], is an easy, fast, and sensitive method for evaluating disorders of visual percep-
tion in mild AD patients. The test includes 15 sheets. Each sheet shows the same picture at dif-
ferent positions in space. The pictures are distorted by choice of special effects: geometric
effects (tile) and the effect of the frame 24/48 of the MGI Photo Suite III program. The patient
had to identify the picture that was properly oriented in space.
Optical coherence tomography (OCT)
The macular thickness retinal and peripapillary nerve fiber layer (RNFL) thickness were mea-
sured by the OCT Model 3D OCT-1000 (Topcon, Japan) and the thickness of the macula was
segmented into layers by OCT Spectralis (Heidelberg Engineering, Heidelberg, Germany),
after pupil dilatation in both cases. The RNFL thickness was scanned 3 consecutive times per
patient in each area studied. The mean values were considered for statistical analysis. All tests
were performed by the same optometrist (ESG) under the same conditions.
The macular thickness was evaluated in two ways: by concentric circular rings and by a
rectangular grid with 6x6 sectors. First, the macular RNFL thickness data were displayed in
three concentric rings centred in the foveola. They were distributed as they appear in Fig 2A.
The total volume of the macula as provided by the OCT was also calculated. The analysis of the
macula using a 6x6 mm grid was performed by centring a grid in the fovea with a scanning
density of 512 x 128 pixels in 3.5s (27,000A scan/s). In total, 36 squares were analysed (1 mm
by 1 mm each). The centre of the macula was defined as the thinnest point of the foveal depres-
sion. The average of each square was noted for analysis (Fig 2B).
The peripapillary RNFL thickness parameters evaluated in this study were: i) average thick-
ness (360˚ measurement); ii) thickness for the four peripapillary quadrants (μm) (Fig 2A) and
iii) thickness for each 12-o’clock hour position with the 3-o’clock position as nasal, 6-o’clock
position as inferior, 9-o’clock position as temporal, and 12-o’clock position as superior (Fig
2B).
The Spectralis OCT software enables the automatic segmentation of the layers of the retina
and the quantification of the thickness of each layer through the same segmentation of concen-
tric circular sectors mentioned above. After collecting the images, a manual check was per-
formed to verify that the fovea was well placed and that the automatic division of the layers
was done correctly. If this procedure failed, the same experienced examiner performed the
layer segmentation manually (Fig 2C).
The good scan criteria were determined as the signal-to-noise ratio >30 and accepted A-
scans >95% in fast RNFL scanning. All measurements were given in microns, according to the
calibration provided by the manufacturers and the total volume was recorded in mm3.
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Statistical analysis
Data for the statistical analysis were introduced and processed in SPSS 19.0 (SPSS Inc., Inc.,
Chicago, IL, USA). The data were reported as median values ± interquartile range. The differ-
ences between different study groups (Mild AD, moderate AD and control eyes) were analysed
using the Mann-Whitney test. Sensitivity was set at 90% specificity, and the area under the
receiver operator characteristic (aROC) analysis was used to discriminate between the healthy
and the mild AD patients. These data were calculated for all the psychophysical tests analysed
and for the OCT analysis. The association between the tests and the MMSE was evaluated
by the Pearson’s correlation coefficient. A P value of� 0,05 was considered statistically
significant.
Results
In the mean MMSE values, there were significant differences between the 3 study groups
(28,58 ± 1,83, control; 25,18 ± 3,80, mild AD; 19,89 ± 2,76, moderate AD; p<0.001, in all
cases). The rest of the data analysed as IOP, gender and race did not present significant differ-
ences between the study groups.
Psychophysical tests
Visual acuity. The median VA both in the mild AD patients and moderate AD patients
significantly decreased in comparison with the age-matched control group (p<0,001) (Table 1,
Fig 3A).
Fig 2. OCT report of retinal thickness analysis. (A) Concentric macular rings and four peripapillary quadrants (B) Rectangular grid 6x6
macular sectors and peripapillary thickness for each 12-o’clock hour and (C) Macular thickness segmentation of 10 retinal layers.
https://doi.org/10.1371/journal.pone.0220535.g002
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Contrast sensitivity. The analysis of CS of the mild AD and moderate AD patients
revealed a statistically significant reduction at all spatial frequencies tested (3, 6, 12, and 18
cpds) in both groups in comparison with age-matched control subjects (p<0,001; in all
instances). In addition, the results of both groups showed that the spatial frequency was higher
when the loss of CS perception was the greater. Thus, in comparison with the age-matched
control group, the spatial frequency of 18 cpds showed the greatest CS decrease in the mild
AD patients and the moderate AD patients (40.67% and 36.98% respectively) (Table 1, Fig 3B).
Colour perception. The analysis of the non-specific total errors in the Farnsworth test
regarding the three groups of the study showed that there was a greater number of non-specific
errors in both the mild AD patients and the moderate AD patients compared with the control
group. In both groups, consisting of the mild and moderate patients, this difference was statis-
tically significant (p<0,05; p<0,001 respectively). The increase in total errors amounted to
30.96% in the mild AD group and over 132.26%, the control group (Table 1, Fig 3C). When
comparing the two groups with AD, more significant errors were found in patients with mod-
erate AD than in patients with mild AD (p<0.001). The increase in errors in patients with
moderate AD was 77.34% with respect to the age-matched controls (Table 1, Fig 3C).
The analysis of the tritan axis revealed that the number of tritan unspecific errors signifi-
cantly increased in both the mild AD patients and the moderate AD patients in comparison
with the age-matched control (p<0,001 in both cases). In addition, significantly more errors
in the tritan axis were found in patients with moderate AD than in patients with mild AD
(p<0.001). The increase in errors found in moderate AD patients corresponded to 49.04%
compared to the age-matched controls (Table 1, Fig 3C).
The analysis of non-specific errors in the deutan axis showed that there were significant
increases in the number of errors in both the mild AD patients and the moderate AD patients
with respect to controls (p<0.05; p<0,001 respectively). This error increase corresponded to
59.89% in the mild AD patients and 158.49% in the moderate AD patients compared to the
control. Finally, when comparing the two groups with AD, significantly more errors were
found in the moderate AD group than in the mild AD group. The error increase in the moder-
ate AD group amounted to 61.71% (Table 1, Fig 3C).
Table 1. Median data and p-value of the psychophysical tests.
Control Mild AD Moderate AD Mild AD vs control Moderate AD vs control Moderate AD vs Mild
AD
(n = 40) (n = 39) (n = 18) % difference P-value % difference P-value % difference P-value
Visual acuity (dec) 1.00 ± 0.10 0.90 ± 0.20 0.90 ± 0.30 -10.00. <0.001�� -10,00 0.003�� 0.00. 0.921
Constrast sensitivity (cpd) 3 1.63 ± 0.29 1.49 ± 0.46 1.49 ± 0.29 -8.59. <0.001�� -8,59 0.009�� 0.00. 0.422
6 1.84 ± 0.44 1.70 ± 0.33 1.55 ± 0.28 -7.61. <0.001�� -15,76 <0.001�� -8.82. 0.373
12 1.54 ± 0.29 1.25 ± 0.32 1.16 ± 0.30 -18.83. <0.001�� -24,68 <0.001�� -7.20. 0.599
18 1.10 ± 0.29 0.64 ± 0.56 0.64 ± 057 -41.82. <0.001�� -41,82 <0.001�� 0.00. 0.781
Number of errors
Total 5.0 ± 5.0 7.0 ± 4.0 12.00 ± 8.0 40.00. 0.034� 140.00. <0.001�� 71.43. 0.001��
Tritan 2.0 ± 2.0 3.0 ± 3.0 6.0 ± 5.0 50.00. 0.002�� 200.00. <0.001�� 100.00. 0.017�
Deutan 1.0 ± 3.0 3.0 ± 3.0 5.0 ± 3.0 200.00. 0.003�� 400.00. <0.001�� 66.67. 0.002��
PDT 14.00 ± 2.00 12.00 ± 4.00 11.50 ± 3.0 -14.29. <0.001�� -17.86. <0.001�� -4.17. 0.650
Median ± interquartile range
�P<0.05
��P<0.01 Mann- Whitney U test
[AD, Alzheimer’s disease; vs: versus; dec: decimal scale; cpd: cicles per degree; PDT: perception digital test]
https://doi.org/10.1371/journal.pone.0220535.t001
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Perception Digital Test (PDT). The PDT mean value found in the age-matched control
group was significantly higher than the value of the mild AD group and the value of the mod-
erate AD group (p<0.001 in both cases) (Table 1, Fig 3D).
Optical coherence tomography
Macular thickness analysis by OCT. In the patients with mild AD, both the thickness
analysis of the circular sectors and the concentric sectors of the macular region revealed signif-
icant decreases. There were also significant decreases in the fovea thickness (p<0.01) and the
sectors of the inner macular ring, superior (p<0.05), the inferior and temporal (p<0.01 in
both cases) with respect to the age-matched controls (Fig 4A). However, in the eyes of the
moderate the AD patients compared to the mild AD patients, there were significant increases
in both the fovea thickness and the inner macular ring thickness in the superior, nasal and
inferior sectors (p<0.05). The maximum increase was recorded in the fovea, being 7.1%
thicker than those of the moderate AD patients (Fig 4A).
Fig 3. Median data of the psychophysical tests. (A) Visual acuity, (B) contrast sensitivity, (C) desaturated Rue 28-hue color test, and (D) perception digital test. Each bar
represents the median ± interquartile range. � P< 0.05 versus control. �� P< 0.01 versus control. Mann-WhitneyU test.
https://doi.org/10.1371/journal.pone.0220535.g003
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The macular quadrangular grid analysis in the eyes of the mild AD patients in comparison
to age-matched controls showed a significant decrease in retinal thickness in squares 6
(p<0.05), 12 (p <0.05), 15 (p<0.01), 21 (p<0.01) and 22 (p<0.01) (Fig 4A). The greatest
decrease in thickness corresponded to square 21 with a -5.5% decrease with respect to the age-
matched control. The moderate AD patients with respect to the mild AD patients, showed a
significant increase in retinal thickness in squares 5 (p<0.05), 6 (p<0.01), 11 (p<0.05), and
21 (p<0.05). The greatest increase in thickness corresponded to squares 6 and 21 with an
increase of 5.2% regarding the mild AD patients (Fig 4A).
Peripapillary RNFL segmentation thickness analysis by OCT. When comparing the
moderate AD patients with the age-matched controls, there was a significant decrease in the
inferior peripapillary sector (p<0.01) and in the average thickness the moderate AD patients
with respect to those of the control patients (p<0.05). When the moderate AD patients were
compared with the mild AD patients, it was found that only the significant decrease in the
lower peripapillary sector persisted (p <0.05). These results, with respect to the control, repre-
sented a decrease of 13.4% in the lower peripapillary sector in the eyes of the mild AD patients
and a thickness decrease of 15% in the eyes of the moderate AD patients (Fig 4B).
When analysing the peripapillary retinal thickness in the 12 hourly sectors, we observed
that only sector 2 in the eyes of the mild AD patients in comparison with those of the age-
matched controls, showed a significant decrease, representing a 10.9% decrease in thickness.
However, when analysing the moderate AD group with respect to the age-matched control
group, it was observed that there was a significant thinning in sectors 1 (p<0.05), sector 2
(p<0.01), sector 3 (p<0.01), sector 7 (p<0.01), sector 8 (p <0.01) and sector 12 (p<0.01).
Most of the thinning was shown in sector 8, the decrease in thickness of which represented
-44.4% with respect to the age control group. The comparison of both the mild and moderate
groups with AD showed that sectors 7 and 8 were significantly thinned in the moderate AD
patients with respect to the mild AD patients. The results showed decreases in thickness of
21.7% and 38.6% respectively. (Fig 4B).
Predictive value of the diagnostic methods. aROC curves
The aROC curve for psychophysical tests in AD patients showed that each test has a high pre-
dictive value (p<0.01). The test with the greatest prognostic value in AD patients was CS for
18 cpd and 12 cpd spatial frequencies, followed by CS for 6 cpd; PDT; unspecific errors in the
deutan region; the tritan region; VA, CS for 3 cpd; and finally unspecific totals errors in Farns-
worth test (Table 2).
The aROC curve in the analysis of the macula by circular concentric sectors illustrated that
the measures that showed statistical significance were the foveal thickness, followed by the
lower sector and temporal of the inner macular ring. The rest of the parameters analysed did
not show statistical significance (Table 2).
The aROC curve values that showed a significant predictive value in the analysis of the mac-
ular thickness by a quadrangular grid of 6x6 were the square 15, the square 16, square 21 and
square 22 (Table 2).
In the aROC curves values for the 12 peripapillary hourly sectors were observed a statistical
significance for sector 2 and sector 8 (Table 2).
Fig 4. Colorimetric percentage differences of retinal thickness between groups. (A) Macular OCT. Upper: OCT concentric circular rings.
Bottom: 6x6 mm rectangular grid, (B) Peripapillary OCT. Upper: Four peripapillary quadrants. Bottom: 12-o’clock hour position
segmentation. In red, thickness decrease; in green thickening. In bold: �P< 0.05. ��P< 0.01. Mann-Whitney U test.
https://doi.org/10.1371/journal.pone.0220535.g004
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Analysis of Pearson’s correlation with the values of MMSE
In the analysis of the Pearson’s correlation between the MMSE scores and the psychophysical
tests, it was found that all the tests had a statistical significance (p<0.001). The highest correla-
tion with the MMSE was found in the CS test in the frequency of 6 cpd with a positive correla-
tion of 0.544 (p<0.001), followed by nonspecific errors of the deutan axis in the analysis of
colour perception with a significant inverse correlation of -0.506 (p<0.001) (a lower MMSE,
more errors); the total errors (r = -0.483; p <0.001); the non-specific errors of the tritan axis
(r = -0.451; p<0.01) that present very high correlations, followed by the SC for 12 cpg (r =
0.439; p< 0.01) and 18 cpg (r = 0.411; p<0.01), VA (r = 0.406, p<0.01), the SC for 3 cpg
(r = 0.386, p<0.01) and TDP (r = 0.257); p<0.01), where in the latter of all positive
correlations.
In the analysis of the correlations between the MMSE scores and the parameters of the
OCT, significant correlations were found in both the measurements of the macular region and
those of the peripapillary region. The highest correlation with the MMSE score and macular
analysis through a 6x6 square grid, was found in square 4 (r = 0.277, p<0.05), followed by
square 6 (r = 0.262, p <0.05), square 12 (r = 0.261, p<0.05), square 24 (r = 0.253, p<0.05),
square 16 (r = 0.243, p<0.05), square 5 (r = 0.242, p<0.05), square 3 (r = 0.238, p<0.05),
square 30 (r = 0.232, p<0.05) and in the concentric sectors analysis the temporal exterior mac-
ular ring (r = 0.229, p<0.05).
The highest to lowest significant correlations of the papillary analysis with the MMSE score
were: in the analysis of hourly sectors, sector 12 (r = 0.370, p<0.01); in the analysis of the 4
sectors, in the superior sector (r = 0.340, p<0.01) and the inferior (r = 0.288, p<0.01), the
average peripapillary thickness (r = 0.308, p <0.01) and finally in the analysis of 12 sectors the
sector 7 (r = 0.278, p<0.01) and 1 (r = 0.260, p<0.01).
Table 2. aROC analysis of psychophysical tests and OCT analysis in Alzheimer’s disease.
aROC SD P-value
Psychophysical tests VA 0,714 0,051 <0,001��
CS 3 0,712 0,052 <0,001��
6 0,795 0,046 <0,001��
12 0,828 0,043 <0,001��
18 0,833 0,040 <0,001��
Color test Total errors 0,702 0,054 0,001��
Tritan errors 0,736 0,051 <0,001��
Deutan errors 0,746 0,051 <0,001��
PDT 0,792 0,045 <0,001��
Macular OCT Fovea 0,708 0,064 0,004��
Inner macular ring Superior 0,638 0,070 0,056
Nasal 0,616 0,072 0,108
Inferior 0,680 0,067 0,013�
Temporal 0,665 0,068 0,022�
Rectangular grid 6x6 macular sectors 15 0,681 0,066 0,012�
16 0,663 0,067 0,024�
21 0,726 0,063 0,002��
22 0,707 0,065 0,004��
�P-value < 0.05
�� P-value < 0.01
(aROC: area under the receiver operating characteristic; AD: Alzheimer’s disease; PDT: perception digital test; SD: standard deviation).
https://doi.org/10.1371/journal.pone.0220535.t002
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The study of all the retinal layers thickness in the macular region through
Spectralis OCT
Thickness of the retinal nerve fiber layer (RNFL) in the macular retina. The eyes of the
mild AD patients, compared to controls, showed a significant thinning of the RNFL in the
inner macular ring in the nasal and inferior sectors, (p<0.05 in both cases) and in the outer
macular ring in the nasal sector (p<0.05). The greatest decrease of thickness in the RNFL was
in the inner macular ring in the lower sector (17.09%) (Fig 5).
Thickness of the ganglion cell layer (GCL) in the macular retina. In the GCL, the eyes
of the mild AD patients with respect to those of the matched age controls showed a significant
thickness decrease in the inner macular ring and in the outer macular ring, in the superior,
nasal and temporal sectors (p<0.05 in all cases). In addition, a significant reduction in the
total volume of the GCL was also found (p<0.05) (Fig 5).
Thickness of the inner plexiform layer (IPL) in the macular retina. In the IPL, there
was a non-significant generalized thinning of this layer at the macular level (Fig 5).
Thickness of the inner nuclear layer (INL) in the macular retina. In the analysis of the
INL, a slight decrease in thickness in the fovea and the superior sectors was observed. In the
rest of the sectors, a slight increase in thickness predominated (Fig 5)
Fig 5. Colorimetric percentage differences of the all retinal layers between mild AD and control group. In red, thickness decrease; in green thickening. �P< 0.05.
��P< 0.01. Mann-WhitneyU test.
https://doi.org/10.1371/journal.pone.0220535.g005
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Thickness of the outer plexiform layer (OPL) in the macular retina. The OPL of the
mild AD patients compared to the matched-age controls showed a significant thickness
decrease in the inner macular ring in the superior sector and the temporal sector (p<0.01,
p<0.05 respectively), in the outer macular ring in the upper sector, and in the total volume of
the OPL (p<0.01, p<0.05 respectively) (Fig 5)
Thickness of the outer nuclear layer (ONL) in the macular retina. In the ONL, the mild
AD patients showed a significant increase in the inner macular ring in the superior sector
(p<0.01) with respect to the matched-age controls (Fig 5).
Thickness of the retinal pigment epithelium (RPE) layer of the macula. In the analysis
of the EPR layer, no significant differences were found in any of the sectors analysed with
respect to the age-matched control (p> 0.05) (Fig 5).
Discussion
To the best of our knowledge, few studies analyse a plenitude of tests and their prognostic val-
ues in the two early stages of AD. One of the noteworthy points of the present study was the
careful selection of the samples. None of the three study groups showed abnormalities or eye
diseases that could mask the results. The sample of patients with AD was very homogeneous in
terms of age, stage of disease, ethnicity, and educational attainment. Patients with mild AD
had high MMSE scores (25.18 ±3.80), higher than any value reported in the different studies
[12–16]. These patients were in a very early stage of the disease. Patients with moderate AD
had MMSE scores (19.89 ± 2.76), which allowed them to understand the instructions to per-
form the tests correctly. The tests were chosen by taking into account the cognitive decline and
possible nominative deficit. VA tests were performed by isolating the letters since they were
dissipated that way, patients with dementia had better values [17]. To measure the CS, we used
the CSV-1000E, with which the patients do not need to verbalize the result. Therefore, the
results were more independent of the VA values [13]. The analysis of the colour perception
was carried out with the Roth 28-hue test since verbalization was not necessary for its realiza-
tion. In the measurements of the retinal thickness by OCT, the patient collaboration was mini-
mal, and the patient was only required to keep an eye open and look fixedly at the fixation
stimulus.
The VA in our patients with mild AD and moderate AD showed a significant decrease with
respect to the control group. In addition, the VA had a significant direct correlation with the
MMSE showing that the VA diminished when cognitive ability decreased in AD. The predic-
tive value of the VA was significant with a value of 71.4%. Although some authors did not find
significant differences in VA in patients with AD [12,15,18–24], other authors found a VA loss
[25,26], associated in some cases with visual hallucinations (13%), when the VA was gravely
impaired [27,28].
The degeneration of the axons of the RGCs in the AD can selectively affect the magnocellu-
lar RGCs [29], which probably constitute the predominant projection of the superior colliculus
(extraocular movements control) and the magnocellular layers of the lateral geniculate
nucleus. In addition, the axons of the RGCs corresponding to the parvocellular pathway
(detail) also diminished in the optic nerve in the AD [30]. In AD patients, more abundant Aβ
plaques in the parvocellular layers were also identified compared to the magnocellular layers.
There was also a presence of neurofibrillary tangles [31,32]. The lack of control of the extraoc-
ular movements link to the damaged parvocellular pathway could result in the VA decrease in
our AD patients. In our study, patients with moderate AD exhibited a decrease in VA with
respect to the control as they did in patients with mild AD. These moderate AD patients did
not show significant differences in comparison with mild AD in spite of a loss of neurons in
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the retina. These findings could be due to adaptation phenomena and neural compensation
[33].
CS in patients with mild AD and moderate AD was significantly reduced at all spatial fre-
quencies. The most pronounced decrease occurred at the highest spatial frequencies. In com-
parison with the controls in the frequency of 18 cpd, the reduction was -40.67 in the mild AD
group and -36.98% in the moderate AD group. This observation suggests that both groups
(mild and moderate) suffered some damage in their function, both in the cells of the parvocel-
lular and the magnocellular pathway. Apparently, the former cells were the most affected. The
CS in moderate AD patients did not present significant changes with respect to mild AD.
These findings suggest that the CS undergoes a steep decline in all spatial frequencies when the
disease begins, and this loss stabilizes with the progression of the disease. This discovery is sim-
ilar to what occurred in VA due to a possible adaptive phenomenon and neural compensation
to maximize the transmission of information [33].
Most studies, including our work, found that the CS function was reduced in all spatial fre-
quencies [12,15,16,20,25,34–37]. Some studies confirmed that the greatest reduction occurs in
high spatial frequencies [16,34,38]. However, other studies showed that the greatest reduction
occurs in the low spatial frequencies [14,15,21,24,39], and some did not find differences
between the controls [18,23]. These discrepancies were possibly due to the different stages of
AD patients and the tests used for the CS examination [13] since some tests are influenced by
the VA value (Regan, Vistech VCTS-6500) while others are not influenced by it (Pelli Robson,
Freiburg and CSV-100E). According to our results, a correlation between CS and retinal struc-
tural changes has been described [24], especially in the macular area. Our aROC values coin-
cided with the most sensitive spatial frequencies, which were 18 cpg (83.3%), followed by 12
cpg (82.8%). These results showed that the CS, specifically when higher frequencies are used,
has the best predictive value of all the psychophysical tests analysed. Therefore, CS is a sensitive
tool to identify subclinical worsening of the visual function [40,41]. In addition, the correlation
analysis in our work showed a strong statistical significance between all the spatial frequencies,
and the MMSE test is a predictive test for the cognitive decline in the AD patients.
The colour perception in our patients did not show dyschromatopsia. However, when we
analysed the total number of non-specific errors in performing the test, we found a significant
increase of errors in moderate AD patients compared to those with mild AD (77,34%) and the
controls (132,26%) both in the tritan region (blue) and in the deutan region (red-green). Some
studies found no differences in colour perception between the AD patients and the control
group [35,42,43]. However, in a more recent work using our colour test, (Farnsworth 28-hue)
our result showed significant differences between patients with moderate AD and the controls
[24]. Furthermore, in our study, patients with mild AD also presented significant differences
in colour perception in the tritan and deutan axes with respect to the control. This fact and the
results obtained in the aROC curves, with predictive values between 70–75%, lead us to postu-
late that chromatic vision examination could constitute a biomarker of the early diagnosis of
AD. The analysis of correlations of non-specific errors of colour perception in the MMSE
score showed that both the total errors and the nonspecific errors of the tritan and deutan
region correlated significantly and inversely with the MMSE score of our AD patients. Results
have been corroborated by other authors using different tests [15,25,44–48]. Nevertheless, the
use of different tests in the analysis of chromatic vision could produce erroneous interpreta-
tions. With respect to the Ishihara test, in its realization, it is necessary to identify a pattern
made of smaller pieces that differ in colour. One of the symptoms suffered by AD patients is
the inability to see the whole of the parts (simultagnosia) due to a bilateral occipital-parietal
dysfunction. Therefore, the Ishihara test would not be adequate to assess patients with AD.
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However, the realization of other tests like Farnsworth, based on the discrimination of tones,
would not be affected by this problem [49].
Some authors have postulated that the problem of colour perception in patients with AD is
not purely cognitive. Nevertheless, it seems to be related to damage in the structures responsi-
ble for the perception of colour stimuli [50]. The increase in nonspecific errors in the tritan
and deutan axes observed in our AD patients suggests that, in addition to the loss of magno-
and parvocellular-cells mentioned above, the koniocellular pathway could also be involved due
to its association with the blue-yellow spectrum [51]. In addition, it has also been described
that patients with AD have a significant reduction in the V4 area, which is a key region that
processes colour vision [52,53]. On the other hand, degeneration in the photoreceptor layer
has also been described in patients with AD, which is not restricted to a single cone type due to
the decrease in melatonin and its antioxidant effects that occur in this pathology [54,55]. Mela-
tonin and its antioxidant effects could be added to the photoreceptor degeneration induced by
Aβ deposits in this layer, as seen in AD animal models [56,57]. In these diseases, a decrease in
the area from the ellipsoids to the EPR was described by OCT, which showed a direct correla-
tion with the degree of cognitive impairment [58].
With respect to PDT, some authors have observed a significant correlation between mild
AD and MMSE values [10]. Our patients with mild AD and moderate AD failed to read a sig-
nificantly larger number of PDT sheets compared to the control patients. This failure could be
due to a disruption of the visual information processing at the brain level [59]. This processing
would take place in the parietal and frontal regions, being mediated by the magnocellular path-
way, which transmits information carrying the low frequencies of CS [60]. As we mentioned
above, it has been described that magnocellular axons, which project to lateral geniculate
nucleus, were affected starting from the early AD stages [29]. In our work, the PDT showed a
high direct correlation with the MMSE scores. Furthermore, the values of the aROC curves
showed a good prognostic value (71.4%). Thus, the PDT could be considered a good test for
the examination of the visual superior processing in AD patients.
In our study involving moderate AD patients, when the peripapillary segmentation was per-
formed in 4 sectors in the OCT, a significant decrease (-15.0%) in the lower sector was
observed with respect to controls. The analysis of the correlations with the MMSE showed that
both the upper and lower sectors had a significant direct correlation with the cognitive state of
the patient. In comparison with the control subjects, it was reported that the eyes of the AD
group showed a reduction of thickness in all peripapillary RNFL quadrants measured by OCT
[61–68]. However, some OCT studies on peripapillary thickness found that the RNFL thinning
was restricted to the superior quadrant [26,69–73] or in the superior and inferior quadrants
[74–77]. These discrepancies could be due to different factors such as i) the inclusion of
patients with different stages of cognitive deterioration in AD ii) the use of different OCT
devices, with different segmentation of the software; and iii) sample selections of patients with
little rigor, including patients with retinal abnormalities such as epiretinal membranes or dru-
sen, which can influence the thickness of the retina. When we examined the peripapillary area
by segmentation into 12 hourly sectors, the eyes of the moderate AD group showed a signifi-
cant thinning in the superonasal and inferotemporal sectors of the papilla with respect to the
controls, while in the patients with mild AD, there was a statistically significant decrease only
in the hour sector 2. These sectors of the papilla are those that showed a better correlation with
the MMSE score and the thinning the superonasal and inferotemporal sectors when the dis-
ease progressed. The aROC curves revealed that the hourly sector 2 and the hourly sector 8
had a high predictive value (71.5% and 66.8% respectively). Only in two studies were the peri-
papillary hourly sectors analysed in detail [62,78]. In one of the works, the patient’s sample
had a greater cognitive deterioration than ours; therefore, it is not comparable [62]. However,
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coinciding with our results, it has been observed that some peripapillary regions were thick-
ened, and others were thinned, being indicative of dynamic changes in the RNFL of the peripa-
pillary area [78].
Some studies showed a thinning of the retina associated with the advance of cognitive
decline when it was correlated with the MMSE score [72,77,79–81], and it has also been
observed that the peripapillary GCL-IPL complex has a strong correlation with the MMSE
[67]. Moreover, in patients with mild AD (MMSE 22.7 ± 2.2), after 12 months of disease evolu-
tion, the peripapillary retinal thickness was significantly decreased in these patients with
respect to the controls. This change was more prominent in the upper and lower regions, and
the decrease in thickness was parallel to the cognitive decline [80]. It has been suggested that
the lower quadrant peripapillary could be the area with greater specificity and sensitivity to
detect cognitive decline in early stages of AD [72,74,80]. In our analysis, only this quadrant
showed a significant correlation with the MMSE score (r = 0.328, p<0.01). This variability of
results may be due to the different stages of the AD patients included in the studies, and to the
methods used to analyse the peripapillary region because many authors segment the papilla
only in 4 sectors, excluding the information provided by the 12 segmentation sectors.
The macular area, which was recently analysed, demonstrated a significant decrease in the
thickness of this retinal region in patients with AD with respect to controls [24,62,71,76,77,82–
87]. However, in some studies, when analysing the foveal area, a non-significant thickening was
found in patients with AD [24,84]. In our study of macular thickness, both the analysis of the con-
centric circular sectors and macular analysis through a 6x6 square grid were carried out in detail
because we consider that the information provided by the analysis of this region represents a great
value, being easy to assess. We observed a foveal thickening (7.1%) in moderate AD, compared
with mild AD, which indicates that there is a progression of the disease. In the analysis of the 6x6
square grid, the thickening, specifically of squares 5, 6, 11 and 21 in moderate AD with respect to
mild AD, also indicated disease progression since we found significant thinning in the squares 6,
12,15, 21 and 22 in patients with mild AD. Aβ and pTau deposits, could produce the aforemen-
tioned thickening [88], which would induce an inflammation with the activation of the microglia
[57], generating, in turn, a cytotoxic effect in the retinal neurons [57,89].
In studies using the latest OCT technology, which allows the separate analysis of the differ-
ent retinal layers, we observed a thinning of the RNFL+GCL complex in AD patients, while
the outer retinal layers were respected [77,79,83]. In addition, a significant reduction in the
complex formed by the GCL and the IPL was described. A positive correlation between the
thickness of the complex with the values of the MMSE in AD was established [90]. It was also
postulated that this complex could have a higher prognostic value than the values of the peripa-
pillary RNFL thickness, and it was related to the decrease in macular blood flow velocity [82].
This degeneration in the innermost layers of the retina was also observed in our mild AD with
a marked thinning in the RNFL, GCL and IPL. The thinning of these internal retinal layers
was also described after analysing 2124 patients from the Rotterdam study, linked to a smaller
volume in the cerebral white and grey matter [91]. In addition, they observed that there was a
significant relationship between the decrease in RNFL and the GCL with a smaller hippocam-
pal volume, which is one of the typical clinical characteristics of AD [91].
In our mild AD patients, in addition to the thinning of some retinal layers, we observed an
increase in thickness in INL and ONL, which could be associated with inflammatory processes
and cellular movements in these outer layers. Moreover, some authors observed macular areas
with significant thickening in the RNFL and in the GCL-IPL complex. These authors found
that the areas of thinning in these two layers were adjacent to areas of thickening, suggesting
that these layers can undergo dynamic changes during the progression of AD [78]. Other stud-
ies have reported a selective increase in the thickness of IPL related to Aβ deposits in the brain
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observed by PET in a preclinical stage of AD patients. In the longitudinal study of these
patients at 27 months, they found a decrease in the volume of the IPL, INL and ONL, in addi-
tion to a thinning in the lower quadrant [92]. The authors explain that the reason for the
increase in IPL in these patients is because acetylcholine is released by different types of ama-
crine, and possibly, by bipolar cells, being the cholinergic synapses concentrated in this layer
[92–94]. Similarly, one of the earliest changes in the brain of AD patients is the neurochemical
changes in the cholinergic system [95], and therefore, the synaptic pathology would be the first
neurotoxic consequence of the progressive neurodegeneration in these patients [96].
On the whole, the findings of all these studies suggest that certain abnormalities in the
brain could be reflected in the retina as the thinning of RNFL, GCL and IPL [97,98]. On the
other hand, the ganglion cell apoptosis can cause anterograde degeneration leading to a thin-
ner RNFL and occasionally cause smaller volumes of white and grey matter in the brain
regions corresponding to the visual tract [99,100].
In conclusion, the first changes in mild AD patients appear in the psychophysical tests and
in the central macula with a decrease of the central retinal thickness, which is the consequence
of the degeneration of the inner layers of the retina. When there was a disease progression to
moderate AD, psychophysical tests remained stable with respect to the decrease in mild AD.
However, a significant thinning in the peripapillary retina and a thickening in the central ret-
ina appeared. Moreover, the thickening in the outer layers and in the INL was significant. The
changes that appear in moderate AD compared with mild AD defined the progress of the dis-
ease correlating significantly with the cognitive decline. The presence of AD is best predicted
based on CS at any frequency (though higher frequencies are better).
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